Complement Receptor C3aR1 Contributes to Paclitaxel-Induced Peripheral Neuropathic Pain in Mice and Rats
The Journal of Immunology · 01.12.2023 · 211 (11) · 1736-1746
DOI: 10.4049/jimmunol.2300252 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 20.10.2023. Verfasst von Jijun Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain Management, Cleveland Clinic, Cleveland, OH. Hauptthemen laut MEDLINE: Paclitaxel, Neuralgia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NEI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Cancer chemotherapy-induced neuropathic pain is a devastating pain syndrome without effective therapies. We previously reported that rats deficient in complement C3, the central component of complement activation cascade, showed a reduced degree of paclitaxel-induced mechanical allodynia (PIMA), suggesting that complement is integrally involved in the pathogenesis of this model. However, the underlying mechanism was unclear. Complement activation leads to the production of C3a, which mediates inflammation through its receptor C3aR1. In this article, we report that the administration of paclitaxel induced a significantly higher expression level of C3aR1 on dorsal root ganglion (DRG) macrophages and expansion of these macrophages in DRGs in wild-type (WT) compared with in C3aR1 knockout (KO) mice. We also found that paclitaxel induced less severe PIMA, along with a reduced DRG expression of transient receptor potential channels of the vanilloid subtype 4 (TRPV4), an essential mediator for PIMA, in C3aR1 KO than in WT mice. Treating WT mice or rats with a C3aR1 antagonist markedly attenuated PIMA in association with downregulated DRG TRPV4 expression, reduced DRG macrophages expansion, suppressed DRG neuron hyperexcitability, and alleviated peripheral intraepidermal nerve fiber loss. Administration of C3aR1 antagonist to TRPV4 KO mice further protected them from PIMA. These results suggest that complement regulates PIMA development through C3aR1 to upregulate TRPV4 on DRG neurons and promote DRG macrophage expansion. Targeting C3aR1 could be a novel therapeutic approach to alleviate this debilitating pain syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pain Management, Cleveland Clinic, Cleveland, OH.
- Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH.
- Department of Neurosciences, Cleveland Clinic, Cleveland, OH.
ORCID-Profile: Jijun Xu, Nozha Borjini, Jin Chen
Förderung
- NCI NIH HHS
- NEI NIH HHS
- NHLBI NIH HHS
- NINDS NIH HHS
- HHS | NIH | National Cancer Institute
- HHS | NIH | National Eye Institute
- HHS | NIH | National Heart, Lung, and Blood Institute
- HHS | NIH | National Institute of Neurological Disorders and Stroke
Zitieren
APA
Xu, J., Huang, P., Bie, B., Dai, Y., Ben-Salem, S., Borjini, N., Zhang, L., Chen, J., Olman, M., Cheng, J., & Lin, F. (2023). Complement Receptor C3aR1 Contributes to Paclitaxel-Induced Peripheral Neuropathic Pain in Mice and Rats. The Journal of Immunology, 211(11), 1736-1746. https://doi.org/10.4049/jimmunol.2300252
Vancouver
Xu J, Huang P, Bie B, Dai Y, Ben-Salem S, Borjini N, et al. Complement Receptor C3aR1 Contributes to Paclitaxel-Induced Peripheral Neuropathic Pain in Mice and Rats. The Journal of Immunology. 2023;211(11):1736-1746. doi:10.4049/jimmunol.2300252
BibTeX
@article{Xu2023,
author = {Xu, Jijun and Huang, Ping and Bie, Bihua and Dai, Yang and Ben-Salem, Salma and Borjini, Nozha and Zhang, Lingjun and Chen, Jin and Olman, Mitchell and Cheng, Jianguo and Lin, Feng},
title = {Complement Receptor C3aR1 Contributes to Paclitaxel-Induced Peripheral Neuropathic Pain in Mice and Rats},
journal = {The Journal of Immunology},
year = {2023},
volume = {211},
number = {11},
pages = {1736--1746},
doi = {10.4049/jimmunol.2300252}
}
EUVIMED